Paris-based Klineo has raised €2 million for its AI platform that facilitates access to cancer clinical trials.
Klineo's platform connects doctors and patients directly to relevant clinical studies. It provides study search, contact with medical centers, and real-time updates and notifications when a new clinical trial meets the patient's criteria.
The startup's solution currently includes studies on skin cancer, breast cancer and lymphoma.
Klineo was founded in 2021 by oncologist Dr. Arnaud Bayle and the two engineers Thomas Peyresblanques and Nicolas Drizard.
The <3 of EU technology
The latest rumors from the EU tech scene, a story from our wise old founder Boris and questionable AI art. It's free in your inbox every week. Join Now!
The startup aims to accelerate patient enrollment in clinical trials, which play a key role in introducing novel and potentially life-saving treatments and offering great hope to people struggling with the disease.
“Today, too few patients benefit from a clinical trial because finding one is a very lengthy process,” said Dr. Arnaud Bayle in a statement.
According to the Cancer Research Institute, fewer than 10% of cancer patients eligible for a clinical trial participate in one. At the same time, around 20% of clinical trials fail due to a lack of participation.
“[Our] “The new solution finally gives doctors and patients the opportunity to easily find new therapy options adapted to the respective situation wherever they are treated, which ultimately enables the progress of medical research,” said Dr. Bayle.
Klineo will use the new funding to cover all types of cancer trials in France by the end of 2024, starting with lung cancer. The startup will also expand its team and improve its platform.
French public investment bank BPI and a number of business angels participated in the round, which marked the company's first fundraising attempt.
In the future, Klineo plans to expand its services beyond France to include studies for other diseases, such as rare and neurological diseases.
Comments are closed.